Your session is about to expire
← Back to Search
Pembrolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new combination of drugs to treat stage IV NSCLC that has spread to the bone. The drugs are Radium-223 dichloride, which is a radioactive agent that kills cancer cells, and pembrolizumab, which is an immunologic checkpoint blocker. The researchers want to measure tumor shrinkage in response to treatment and how long that shrinkage lasts.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the most typical application of Pembrolizumab?
"Pembrolizumab is frequently employed to treat malignant neoplasms, but it can also be utilized on unresectable melanoma, microsatellite instability high. Furthermore, this drug has been found to help patients in the event of chemotherapy-induced disease progression."
What prior investigations have included Pembrolizumab in their protocols?
"Currently, Pembrolizumab is being studied in 967 different medical trials with 125 of those studies in their third phase. Most research centres are based out of Houston, Texas but there exists a network of 36090 locations conducting clinical trials for the medication."
What is the maximum number of enrollees for this experiment?
"Unfortunately, this trial has concluded its recruitment phase. Initially posted on March 6th 2020, it was last updated November 7th 2022. For those searching for other studies related to carcinoma non-small cell lung and Pembrolizumab respectively, 1361 and 967 clinical trials are presently accepting patients."
Are individuals being enrolled in this experiment at present?
"At the present moment, this clinical trial is not recruiting. Initially posted on March 6th 2020 and most recently updated November 7th 2022, prospective participants should look to other studies for their medical needs. For instance, there are currently 1361 trials admitting patients with carcinoma non-small-cell lung cancer as well as 967 studies actively enrolling those seeking pembrolizumab treatment."
What adverse effects should patients be aware of when taking Pembrolizumab?
"The safety of pembrolizumab has only been tested to a limited degree, so it received the lowest score on our rating scale of 1."
Share this study with friends
Copy Link
Messenger